Interventions of Interest:

  • AMX0035 (RELYVRIO™, Amylyx Pharmaceuticals, Inc.)
  • oral edaravone (Mitsubishi Tanabe Pharma Development America, Inc.)

Relyvrio was removed from the market on April 4, 2024. Read ICER’s commentary on Amylyx’s decision to discontinue the drug here.

Final Documents

Final Evidence Report and Meeting SummaryDownload
Final Policy RecommendationsDownload
Report-at-a-GlanceDownload
Draft Evidence ReportDownload
Responses to Public CommentsDownload

ICER’s Chief Medical Officer, David Rind, MD stated:

“The votes of the Midwest CEPAC reflected the remaining uncertainties around the benefits of these therapies and the overwhelming certainty that $170,000 per year is much too high a price for either therapy despite the overwhelming need for treatments for this devastating disease.“

For questions, please contact info@icer.org.

View the Key Stakeholder List.